Key Highlights

  • ORIC closed up 8.33% at $13.78 on October 20, up 17.98% over the week and 7.57% over the month, with a market capitalization of about $1.43 billion.
  • The second-quarter net loss was $41.5 million, or $0.38 per share.
  • Cash and investments were $387.6 million at June 30, which the company said funds operations into the second half of 2028.
  • The Phase 3 Himalayas-1 study of rinzimetostat plans to enroll about 600 patients at more than 250 sites.
  • The company planned to present first-line enozertinib data in atypical EGFR mutations at the ESMO congress in October.

What Is Behind ORIC's 18% Weekly Gain, and Is the ESMO Presentation What Investors Are Missing?

ORIC Pharmaceuticals (NASDAQ:ORIC) closed up 8.33% at $13.78 on October 20 and is up 17.98% over the week, for a market capitalization of about $1.43 billion. The stock has gained 7.57% over the past month. No announcement was identified for the week of its advance.

The nearest data event was planned for October, when ORIC said it would present first-line enozertinib monotherapy data in patients with atypical EGFR mutations at the ESMO congress. No release confirming the presentation was found, so the link to the stock's move is unconfirmed.

What Does ORIC Develop, and How Large Is the Rinzimetostat Phase 3 Study?

ORIC develops rinzimetostat, a PRC2 inhibitor for prostate cancer, and enozertinib, an EGFR inhibitor for lung cancer. The company has no revenue.

It has started the Phase 3 Himalayas-1 study of rinzimetostat in metastatic castration-resistant prostate cancer, which plans to enroll about 600 patients at more than 250 sites. Bayer supplies darolutamide for the combination at no cost, and ORIC retains global rights to rinzimetostat.

How Long Does ORIC's $387.6 Million Cash Balance Last?

In its second-quarter report on August 3, ORIC posted a net loss of $41.5 million, or $0.38 per share, and said cash and investments were $387.6 million at June 30. That total includes $59.9 million of at-the-market proceeds raised in the first quarter, and the company said it funds operations into the second half of 2028.

At the second-quarter net loss, the cash would cover about 9.3 quarters, a calculated figure consistent with the stated runway. Cash equals about 27% of the market capitalization, also calculated. The date of the third-quarter report had not been confirmed in the sources reviewed.

How Does ORIC Compare With Nurix, Which Is Also Up 18% This Week?

Nurix Therapeutics (NASDAQ:NRIX) closed up 4.89% at $26.10 on October 20 and is up 17.78% over the week, for a market value of about $2.85 billion. Its fiscal third-quarter profit of $549.8 million came from Roche-related revenue and deal accounting rather than operations, and it held $1.1 billion in cash and marketable securities, about 39% of its market value.

The weekly gains of 17.98% and 17.78% are almost identical, though only Nurix has a dated disclosure just before the rally. ORIC's calendar is data-driven, while Nurix's profit will not repeat.

Which Second-Half Data Updates Come Next for ORIC?

Further updates are scheduled for the second half of 2026, including exon 20 monotherapy data, data from a subcutaneous amivantamab combination and a rinzimetostat program update. A decision on a registrational trial for enozertinib is expected to follow those clinical updates. With a runway into the second half of 2028, the company faces limited near-term financing risk while those checkpoints arrive.